Legal / IP

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer
HKG: 6628Patents

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer

Transcenta Holding Limited (HKG: 6628) announced that it has been granted an invention patent by the China National Intellectual Property Administration (CNIPA) covering the anti-CLDN18.2 antibodies independently developed by the…

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
AstraZenecaBiotech

Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief

Boehringer IngelheimCSPC Pharmaceutical

Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta

ADC / XDCCancer

ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO

Acer TherapeuticsRelief Therapeutics

Acer Therapeutics and Relief Therapeutics Awarded China Patent for ACER-001

Show More